29 March 2017 - PRESS RELEASE

New malaria prophylaxis promising in clinical trial

Researchers from the University of Tübingen and the DZIF show medicine is effective when the timing is right. Their new active substance – DSM 265 – demonstrated a good prophylactic effect for Malaria. 21 healthy volunteers participated in the trial. The results have been published in the medical journal The Lancet Infectious Diseases. 

Moskitonetz_BK_Kapella__M.D.___CDR__USPHS__800.jpg

Mosquito nets: first protection against malaria© BK Kapella (CDR, USPHS)

Over 100 million travelers from temperate regions visit malaria-risk areas every year. Some 30,000 become infected with the pathogen Plasmodium falciparum, which is spread by the Anopheles mosquito. There are various drugs available which can prevent malaria. But some can have serious side effects; others must be taken every day to be effective. Forgetting to take the anti-malaria tablets is currently the biggest risk factor for travelers when it comes to contracting the disease.

Researchers headed by Professor Peter Kremsner and Dr. Benjamin Mordmüller at the Institute of Tropical Medicine of the University of Tübingen and the German Center for Infection Research (DZIF) have run the first clinical trials on a new agent, DSM265. In a study supported by MMV (Medicines for Malaria Venture) and the DZIF, healthy volunteers were infected with malaria parasites after taking the new active substance; DSM265 demonstrated a good prophylactic effect. The substance inhibits a Plasmodium-specific metabolic chain and thus its replication in the human liver and the in the blood can be stopped. “Theoretically DSM265 can stop an infection by Plasmodium straight after the mosquito bite,” says Professor Kremsner.

In the trial, 21 healthy volunteers who had never had malaria were given either a single dose of DSM265, placebo, or an already established drug for malaria prevention. It was a double-blind experiment, which means neither the study participants nor the investigators knew which participant was in which group. One or seven days after taking DSM265 all the participants were infected with malaria parasites and treated with a highly effective drug immediately when first parasites appear in the blood. “As was expected, all volunteers in the placebo group developed malaria. The participants who took DSM265 one day previously were fully protected against the disease,” Dr. Mordmüller explains. “Taking it seven days prior to infection was only partially efficacious, but there are ways to improve that, for instance by increasing the dose.” Safety and tolerability of DSM265 was very good. “We need to do a lot more studies yet. But this first clinical trial has been very promising,” says the manuscript´s first author, Dr. Mihály Sulyok. Now the development of DSM265 as a malaria prophylaxis effective in the long term can go ahead.


Publication

Mihály Sulyok, Thomas Rückle, Alexandra Roth, Raymund E Mürbeth, Stephan Chalon, Nicola Kerr, Sonia Schieper Samec, Nathalie Gobeau, Carlos Lamsfus Calle, Javier Ibanez, Zita Sulyok, Jana Held, Tamirat Gebru, Patricia Granados, Sina Brückner, Christian Nguetse, Juliana Mengue, Albert Lalremruata, Kim Lee Sim, Stephen L Hoffman, Jörg J Möhrle, Peter G Kremsner, Benjamin Mordmüller: DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. The Lancet Infectious Diseases, dx.doi.org/10.1016/S1473-3099(17)30139-1

Press Release University of Tübingen


Contact

Prof Peter Kremsner
Universitätsklinikum Tübingen/Universität Tübingen
Institut für Tropenmedizin
German Center for Infection Research
T +49 7071 29-87179
E-Mail 

Dr Benjamin Mordmüller
Universitätsklinikum Tübingen/Universität Tübingen
Institut für Tropenmedizin
German Center for Infection Research
T +49 7071 29-85446
E-Mail

DZIF Press Office
Janna Schmidt und Karola Neubert
T +49 531 6181-1170/1154
E-Mail



Back to List